Cannabidiol in Sickle Cell Disease

Clinical Trial
Study Details
Enrollment
52
Interventions
Description

Cannabidiol (CBD) twice daily taken orally for 4-weeks

Name
Cannabidiol
Type
Drug
Description

Placebo equivalent twice daily taken orally for 4-weeks

Name
Placebo
Type
Drug
Phase
Phase 1
Phase 2
Status
RECRUITING
Study ID #
NCT06930703
Study Type
Interventional
Summary

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

Study Overview
Conditions
Description

The researchers will conduct a randomized, double blind, placebo-controlled, study of cannabidiol in an oral formulation. Participants will be enrolled when they are not in pain crisis and have demonstrated a urine toxicology test free from cannabinoids in the past 30 days. The sample size will be 52 participants, aged ≥18, with 1:1:1:1 allocation of placebo to 3 drug doses. This is a dose finding study with a primary outcome of reduction of inflammatory cytokine TNFα.

Contacts and Locations
Locations
Facility

Icahn School of Medicine at Mount Sinai
Manhattan, New York 10029
United States

GeoPoint
40.78343, -73.96625
Status
Recruiting